Intercept Pharmaceuticals Inc (ICPT)

96.20
NASDAQ : Health Care
Prev Close 96.20
Day Low/High 0.00 / 0.00
52 Wk Low/High 85.88 / 172.95
Avg Volume 633.80K
Exchange NASDAQ
Shares Outstanding 25.10M
Market Cap 2.40B
EPS -16.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Clovis Sell-Off May Be Overdone

Clovis Sell-Off May Be Overdone

Clovis Oncology, Intercept Pharmaceuticals and Editas Medicine were among the biotech premarket movers on July 31.

These Are the Best Growth Stocks Right Now in Biotech

These Are the Best Growth Stocks Right Now in Biotech

Top names.

3 Red-Hot Biotech Stocks That Could Get Even Hotter

3 Red-Hot Biotech Stocks That Could Get Even Hotter

An analyst weighs in.

Here Comes a Big Breakout For Alibaba

Here Comes a Big Breakout For Alibaba

What the charts say.

Health Canada Grants Approval For Ocaliva™ (obeticholic Acid) For The Treatment Of Patients With Primary Biliary Cholangitis (PBC)

Ocaliva represents the first new treatment option in over 20 years for PBC, an autoimmune liver disease that is the leading reason for liver transplantation in women in Canada 

Biotech Movers: Paratek Spikes 34%

Biotech Movers: Paratek Spikes 34%

Paratek Pharmaceuticals, Immunomedics and Intercept Pharmaceuticals were among the biotech stock movers in premarket trading Tuesday.

Full Speed Ahead; Big Moves: Best of Kass

Full Speed Ahead; Big Moves: Best of Kass

In highlights from this week's trading diary and posts, Kass offers some advice about fundamentals and about what earnings season means.

Intercept Pharmaceuticals Plans Changes to Its Fatty Liver Disease Study

Intercept Pharmaceuticals Plans Changes to Its Fatty Liver Disease Study

Intercept says it received approval from the FDA.

Intercept Pharma: We Can't Enroll Our NASH Study so We're Changing the Study. Trust Us, All Good

Intercept Pharma: We Can't Enroll Our NASH Study so We're Changing the Study. Trust Us, All Good

Intercept claims FDA approved the OCA study modifications, but like most pharma companies, no proof was offered, just verbal assurances.

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

The companies inked a $250 million deal on Friday that could be worth up to $2 billion, thanks to milestone payments.

TheStreet Quant Rating: D- (Sell)